Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Sunitinib—a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor

Nature Clinical Practice Oncology volume 4, pages 342–343 (2007)Cite this article

boxed-textDemetri GD et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349

    Article  CAS  Google Scholar 

  2. Debiec-Rychter M et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093–1103

    Article  CAS  Google Scholar 

  3. Heinrich MC et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764–4774

    Article  CAS  Google Scholar 

  4. Prenen H et al. (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622–2627

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Human Genetics, Catholic University of Leuven, Herestraat 49, B–3000 Leuven, Belgium maria.debiec-rychter@med.kuleuven.be

Authors and Affiliations

  1. M Debiec-Rychter is an Associate Professor in the Department of Human Genetics at the Catholic University of Leuven, Leuven, Belgium.,

    Maria Debiec-Rychter

Authors
  1. Maria Debiec-Rychter
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Debiec-Rychter, M. Sunitinib—a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor. Nat Rev Clin Oncol 4, 342–343 (2007). https://doi.org/10.1038/ncponc0814

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0814

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing